GlassScriptPhysician profile
Tolga Icli
NPI 1114182979
$11,442.27
in general payments reported to CMS, 2019-2025
43 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $1,148 · 2021: $1,775 · 2022: $2,415 · 2023: $2,653 · 2024: $2,108 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,762 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,761.68 |
| Education | $155.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,446.27 | 2019-2025 | |
| Novo Nordisk INC | $1,439.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,028.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $981.87 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $874.81 | 2019-2025 | |
| Amarin Pharma, INC. | $782.84 | 2019-2023 | |
| Amgen INC. | $631.74 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $621.80 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $411.63 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $377.18 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.75 | 2019-2024 | Tradjenta, Jardiance, Synjardy |
| Astellas Pharma US INC | $307.51 | 2022-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $288.91 | 2021-2024 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $277.50 | 2022-2024 | |
| Abbott Laboratories | $269.36 | 2022-2024 | Freestyle Libre 3 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tolga Icli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.